Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 18 of the 49 sources its claims cite were checked for support.

Retatrutide—A Game Changer in Obesity Pharmacotherapy

Open access

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy. This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide's mechanisms, efficacy, and safety profile. Retatrutide's unique molecular structure enables potent activation of GLP-1, GIP, and glucagon receptors, leading to significant weight reduction, improved glycemic control, and favorable metabolic outcomes. Animal studies demonstrate retatrutide's ability to delay gastric emptying, reduce food intake, and promote weight loss, with superior efficacy compared to other incretin-based therapies. Phase I and II clinical trials corroborate these findings, showing dose-dependent weight loss, reductions in Glycated Hemoglobin (HbA1c) levels, and improvements in liver steatosis and diabetic kidney disease. Common adverse effects are primarily gastrointestinal and dose-related. Ongoing Phase III trials, such as the TRIUMPH studies, aim to further evaluate retatrutide's long-term safety and efficacy in diverse patient populations. While retatrutide shows immense promise, considerations regarding cost and the quality of weight loss beyond BMI reduction warrant further investigation. Retatrutide heralds a new era in obesity and T2DM treatment, offering hope for improved patient outcomes.

Overview

CoChat Summary

TL;DR

This is a narrative review of retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, arguing that it is a promising new option for obesity and T2DM. The paper reports strong phase I/II signals for weight loss, HbA1c reduction, and liver-fat improvement, but emphasizes that phase III data, cost issues, and body-composition outcomes are still needed.

Key findings

  • In a phase 1 study, 47 healthy individuals entered and 45 received at least one dose; retatrutide reached maximum concentration in 12–72 h, had a mean half-life of about 6 days, and reduced body weight at all dose levels except 0.1 mg.
  • In a 48-week phase II obesity trial, 338 adults were enrolled; least-squares mean body-weight change at 24 weeks ranged from −7.2% (1 mg) to −17.5% (12 mg) versus −1.6% with placebo, and at 48 weeks from −8.7% (1 mg) to −24.2% (12 mg) versus −2.1% with placebo.
  • In a phase II diabetes trial, HbA1c at 24 weeks fell by up to −2.02% in the 12 mg escalation group versus −0.01% with placebo; body weight at 36 weeks decreased by up to 16.94% in the 12 mg escalation group.
  • In a liver-fat substudy, 98 patients with ≥10% liver fat were randomized; mean relative liver-fat change at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), and −82.4% (12 mg), versus +0.3% with placebo, and 76 participants completed the substudy.

Methods

  • Narrative literature review using Medline with the keywords retatrutide, T2DM, obesity, and novel pharmacotherapy, combined with AND/OR.
  • Included English-language articles published from 2005 onward; the most recent search was in April 2025.
  • The paper synthesizes preclinical and clinical studies, including phase I and II trials and animal experiments, to describe mechanism, efficacy, and safety.

Limitations

  • The paper states that additional phase 3 clinical trials are crucial to further evaluate safety and long-term effects.
  • The paper states that cost may limit access to retatrutide.
  • The paper states that studies assessing the quality of weight loss beyond BMI reduction are lacking.
  • Evident from the text: this is a review, not an original study, so its conclusions depend on the included studies rather than new primary data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/biom15060796

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Retatrutide’s mechanisms of action.
Figure 1 Retatrutide’s mechanisms of action.CC BY · PubMed Central
Figure 2 The present and future of Retatrutide.
Figure 2 The present and future of Retatrutide.CC BY · PubMed Central

Verification

Claims the paper makes

18 Valid · 1 Not valid · 32 Not checked · 8 Own results and interpretations

23 more claims · 7 with their cited sources checked

Create a free account to see all 59 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Cited by

See all 29

Metadata

Authors
Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K.
Affiliations
National and Kapodistrian University of Athens (GR)
Corresponding author
Katsi, Vasiliki
Venue
Biomolecules
Publisher
MDPI AG
Published
2025-05-30
Volume
15
Issue
6
Pages
796
ISSN
2218-273X (ISSN-L)
OpenAlex
W4410951277
Cited by
29
References
50
Citations by year
2026: 27 · 2025: 2
FWCI
3.89
Type
journal article
Language
en
Open access
Locations
  • Biomolecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
retatrutide, obesity pharmacotherapy, type 2 diabetes, GLP-1 receptor, GIP receptor, glucagon receptor, weight loss, glycemic control, HbA1c, non-alcoholic fatty liver disease, diabetic nephropathy, incretin-based therapy, gastrointestinal adverse effects
MeSH terms
Animals, Diabetes Mellitus, Type 2, Fatty Acids, Gastric Inhibitory Polypeptide, Humans, Obesity, Peptides, Weight Loss, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Retatrutide—A Game Changer in Obesity Pharmacotherapy. https://app.cochat.ai/papers/10.3390/biom15060796
The paper
Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025). Retatrutide—A Game Changer in Obesity Pharmacotherapy. Biomolecules. https://doi.org/10.3390/biom15060796

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.